Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$338.91 USD
+26.80 (8.59%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $335.58 -3.33 (-0.98%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Madrigal Pharmaceuticals, Inc. has a market cap of $6.93B, which represents its share price of $312.11 multiplied by its outstanding shares number of 22.20M. As a mid-cap company, MDGL's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MDGL 338.91 +26.80(8.59%)
Will MDGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Other News for MDGL
Madrigal Pharmaceuticals price target raised by $8 at Canaccord, here's why
Janus Henderson Opportunistic Alpha Managed Account Q2 2025 Commentary
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ...
Q2 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT Insight